Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://patents.google.com/patent/US20160286891A1/en
core patent that BRKK owned
thank you for the information, can somebody look into the patent that Brkk owned, if anyone has knowledge on patents, any insightful points on it?
Have you studied Y-90 RadioGel? IIts cutting edge biotech and new way to kill cancer, with many advantages over even other biotechs using Y-90; and now its version for the animal, isopet, now is being used for the treatment of animal soft tissue sarcomas.
No one else has their proprietary Radio Gel....here are some advantages - and when you compare the below to traditioinal chemotherapry well its easy to see the potential here. And biotechs are valued by their potential as many dont ever even come to market yet their market caps are well over $100 mil.:
. What are the advantages of RadioGel™?
Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:
•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.
•Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.
•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.
•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.
•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.
•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.
All are expected in THIS MONTH OF APRIL or soon in this year !!!!!!
UPDATED deals on the removal of toxic debts !!!!!!
Deals of partnerships!!!!!!
STOP SIGN REMOVAL!!!!! CURRENT FILER ON THE OTC!!!!!
NEW WEBSITE TO BE LAUNCHED!!!!
Patent to be granted!!!!!!
STOCK BUYBACK PROGRAM!!!!!!
Possible buyouts !!!!!!
https://www.otcmarkets.com/stock/BRKK/news/story?e&id=1314760
HENDERSON, Nevada, March 21, 2019 /PRNewswire/ -- BRK, Inc. (the "Company") (OTC:BRKK) is pleased to announce they have executed a Settlement Agreement with Auctus Fund, LLC to retire their outstanding convertible debt and release the Company of a $700,000 judgment against it for $185,000. BRK expects the General Release of All Claims executed by both parties to be filed in court later this month. A further announcement will be made once completed. In addition, the Company's legal team is pursuing enforcement procedures to begin collecting on BRK's $2.4 Million judgment against iSee Automation and are applying to have the judgment enforced in Canada as well.
These preparations also include additional court proceedings, to continue with the protection and enforcement of BRK's valuable intellectual property rights. These proceedings will include claims in Canada and the United States against both corporate and individual defendants in their personal capacity. It is BRK's position that the ongoing continued infringement of its valuable rights has been done with full knowledge and intent, including the establishment of new companies created with full knowledge and solely for the purpose of pursuing these unlawful and infringing activities. Daniel Serruya CEO BRK, Inc. commented, "Management is excited to have the Company's largest debt holder off the balance sheet as we move forward with growing the Company. Our first priority was to defend our Intellectual Property then clean the balance sheet of the toxic debt put in place by previous management. With close to $1 million of debt removed from the balance sheet since January, mostly consisting of the highly dilutive toxic debt, it has allowed management to concentrate on developing partnerships and business relationships to begin generating top line revenue."
Mr. Serruya continued, "With the successful lawsuit and $2.4 Million judgment, management would like to announce a plan to use 50% of the judgment proceeds to buyback shares of the Company in the open market. Management feels the shareholders should also benefit in a more direct manner for their continued support of BRK, Inc. In addition, if the Company is successful in any other lawsuits or settlements for IP infringement, management will apply the same standard to any further judgments."
based on what?
I liked the picture more than your claims :)
great, debt free is very important for brkk to grow organically. after that remove the stop sign and buy back shares.
that is a wonderful expectation for the tech application!!! Yes, if BRKK gets the patent granted soon, this will shot to the moon
That was clearly in the company letter to investors. For sure it will happen unless the company has a partnership deal in hand.
here comes another prophet, keep hope body, this will be in clinics
mumble and jumble, who cares what you said
You are a genius dreamer, wish dream comes true, we all are happy!
I like that Corruption Fighter, hope holding steadfast along this journey
smart rebuttal!!!
Thank you for clarifying it. I am long and holding strong with this. I have a paper loss of significance. However, I will have some gain eventually.
Hopefully, RDGL needs to hurry up in dog sarcoma treatment cases, then strongly support proceeding to human clinics trials. Somebody with a business mindset can help with partnership deals. High cancer incidence country like China may look for this potential choice of injectable and internal radiotherapy, somebody needs to stand up for making that resource connection.
good angle of thinking big in Vivos, when this is going for clinical trial, the PR will be dollars
is that real, man?
I had like posting a piece of useful information here
https://www.emergogroup.com/sites/default/files/emergo-fda-510k-data-analysis-2017.pdf
Great info, thanks
thank you, hope it will be this week
haha, somebody knows something, insiders are buying
Thank you, I think this is a promising one. Hope the patent gets granted soon which will make a huge difference.
haha, mumble and jumble
good, honest and sincere tone, thank you for sharing, I am holding bags, but hope break even and get a little rewards.
what I invested had similar down as yours, but I have faith this will go up vigorously.
Haha, really, you look more like a prophet now
how do you know, are you a prophet?
hi glad you are here. what is your factual DD? would like to hear your opinion.
Very clear points, I agree with you. Things are getting better, at least Daniel is working hard towards good direction. Hope patent will be granted soon and well-design website will be released also. All of that will push it to high
great, thanks for sharing your thought
Thank you for contacting Daniel about concerns, can you kindly address the questions and concerns as mentioned in the previous message?
I have sent a message to Mr. Daniel but did not get any reply, can you help to send to him?
please help to forward this message to Mr.Daniel, thank you
Hi Mr. Daniel, thank you for working hard for BRKK, I am an investor here, wish to see good things coming soon with the company. very excited about the progress you had made to bring the company up.
there are my concerns and questions:
1 why untill now the BRKK does not have a nice designed and updated well company website, which is not that great for make good public exposure.
2. what is the total OS and.AS?
3. How much is the debt that company is holding liability?
4 what are near progress with the company?
thank you and have a great weekend
bdvest
Do not blindly bash, go there and check for us, we pay your bill of trip
BRKK NEWS
Thursday, March 21 2019 8:30 AM, EST BRK, Inc. Enters Settlement Agreement With Auctus Fund, LLC and Sets Collection Procedure for $2.4 Million Judgment With a Share Buyback Plan PR Newswire "Press Releases US - English"
HENDERSON, Nevada , March 21, 2019 /PRNewswire/ -- BRK, Inc. (the "Company") (OTC:BRKK) is pleased to announce they have executed a Settlement Agreement with Auctus Fund, LLC to retire their outstanding convertible debt and release the Company of a $700,000 judgment against it for $185,000 . BRK expects the General Release of All Claims executed by both parties to be filed in court later this month. A further announcement will be made once completed. In addition, the Company's legal team is pursuing enforcement procedures to begin collecting on BRK's $2.4 Million judgment against iSee Automation and are applying to have the judgment enforced in Canada as well.
These preparations also include additional court proceedings, to continue with the protection and enforcement of BRK's valuable intellectual property rights. These proceedings will include claims in Canada and the United States against both corporate and individual defendants in their personal capacity. It is BRK's position that the ongoing continued infringement of its valuable rights has been done with full knowledge and intent, including the establishment of new companies created with full knowledge and solely for the purpose of pursuing these unlawful and infringing activities.Daniel Serruya CEO BRK, Inc. commented, "Management is excited to have the Company's largest debt holder off the balance sheet as we move forward with growing the Company. Our first priority was to defend our Intellectual Property then clean the balance sheet of the toxic debt put in place by previous management. With close to $1 million of debt removed from the balance sheet since January, mostly consisting of the highly dilutive toxic debt, it has allowed management to concentrate on developing partnerships and business relationships to begin generating top line revenue."
Mr. Serruya continued, "With the successful lawsuit and $2.4 Million judgment, management would like to announce a plan to use 50% of the judgment proceeds to buyback shares of the Company in the open market. Management feels the shareholders should also benefit in a more direct manner for their continued support of BRK, Inc. In addition, if the Company is successful in any other lawsuits or settlements for IP infringement, management will apply the same standard to any further judgments."
About BRK, Inc.
BRK Inc . (OTC PINK: BRKK), established in 2008, is owner of the Helmet Camera intellectual property (patents-pending) that make the RefCam possible. With the acquisition of the live broadcast helmet camera patent, BRK is poised to enter sports marketing in a big way. iSee Sports Inc. is a wholly owned subsidiary of BRK, Inc.
The foregoing contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are intended to be covered by the safe harbor provisions of the federal securities laws. Forward-looking statements often contain words such as "will," "anticipate," "believe," "plan," "estimate," "expect," "intend," "is targeting," "may," "should," ''poised,'' and other similar words or expressions. Forward-looking statements are made based upon management's current expectations and beliefs and are not guarantees of future performance. Our actual business, financial condition or results of operations may differ materially from those suggested by forward-looking statements as a result of risks and uncertainties which include, among others, those described in any of our other filings with the SEC.In addition, such statements could be affected by risks and uncertainties related to: (i) commercialization of our newly-acquired helmet camera, (ii) continuing development and protection of our intellectual property, (iii) unexpected industry competition, (iv) the need to raise capital to meet business requirements, and (v) our ability to sell our products in order to generate revenues. Forward-Looking Statements are pertinent only as of the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, future developments or otherwise. Any future public statements or disclosures modifying any of the forward-looking statements contained in or accompanying this news release, will be deemed to supersede such statements in this news release. Information on BRK Inc.'s website,http://www.brkincorporated.comdoes not constitute a part of this release.
Contact: shareholder@brkincorporated.com +1-(702)-572-8050
brkincorporated.com
when situation is ready, the info will be there for sure
Richland WA, March 04, 2019 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTCPINK: RDGL), provides a summary of the previous update on dogs that have been treated to date in the canine soft tissue sarcoma series.
Dr. Mike Korenko, Vivos Inc CEO stated “On February 25, 2019 we provided a detailed update on the status of dogs that have been treated to date with Y-90 IsoPet at the University of Missouri Center for Veterinary Medicine. Reporting results on therapies at the University of Missouri requires their review and approval. As a result, the last press release was technically accurate, but included terminology commonly used by veterinary professionals but not generally understood by the general public. For that reason, I believe that it is necessary to provide the following summary observations:
IsoPet® is easily administered in an outpatient setting using the procedures provided in the product labeling.
IsoPet® killed any cancer cells that came within the treatment zone.
Biologically it takes time for the dead tissue to resorb, but the rate and quality of normal tissue regeneration is encouraging.
I am confident that IsoPet extended the duration and quality of life of the patients that were treated.
I was particularly impressed that IsoPet effectively stopped the growth of a half-pound tumor.
IsoPet® is a great product and we are looking forward to making it available commercially.”
I like your believing in this, that is why I hold on it even having paper loss hugely.
that is the situation for me now. Hope this company is doing well and move forwards as it plans. I am still holding confidence in this product, did not say any reason why it can not get real or available to cancer patients